ACM Global Central Laboratory, a diagnostic central laboratory delivering high-quality testing services that optimize clinical trial outcomes, is pleased to announce that it has officially opened the doors at its new Singapore lab facility. The opening of ACM Singapore, as well as the impending ACM Shanghai location, is a derivative of ACM Global’s acquisition of Phoenix Pharma Central Services Pte. Ltd (Phoenix PCS), a premier central laboratory services provider for Asia Pacific clinical trials. The fully-operational lab comes staffed by a local team that has extensive clinical trials experience and knowledge of regional regulatory requirements, providing local support throughout the Asia Pacific region with increased speed and efficiency.
“We have successfully provided central laboratory services in the Asia-Pacific region for more than 15 years, but with the addition of an ACM Global owned and operated lab, we’re able to offer our clients new levels of efficiency and operational control in an increasingly important region for clinical research,” said Jerry Boxall, managing director, ACM Europe and Asia. “This facility is truly an extension of our operations in the United States, the United Kingdom and China, and has been specifically designed to deliver global clinical trial services in the same seamless and time-efficient manner as they would from any of our other established facilities.”
Located in the heart of Singapore and just five minutes from the Singapore International Airport, the facility features approximately 5,000 square feet of laboratory space and is equipped with ACM Global’s standard technology platforms and instrumentation to enable seamless integration with its global network of laboratories. The Singapore lab, which has been accredited by the College of American Pathologists (CAP) since 2003, offers a broad menu of safety and specialty testing, including chemistry, hematology, urinalysis, and immunology testing. Chiew Yan Lee, PhD, FRCPath, who joined ACM Global from Phoenix PCS as Director, Singapore and China Operations and has more than 20 years' experience in central laboratory operations within the Asia-Pacific region, will oversee the Singapore and Shanghai facilities, staff and operations.
The addition of ACM owned and operated laboratories in Singapore and Shanghai is the latest in a series of growth-driven investments made by ACM Global, which in 2013 moved its European laboratory operations into a new, purpose-built, and expanded facility in York, England. Since 1994, ACM Global has provided central laboratory testing services to more than 2,300 clinical studies, involving more than 7,000 investigator sites in 60 countries, giving the company a broad range of global experience and an in-depth understanding of regional requirements.
To learn more information on ACM Global's central lab services and experience in the region, please call 1-866-405-0400 or visit www.acmgloballab.com/asiapac.
ACM Global Central Laboratory specializes in delivering high quality central laboratory testing services designed to optimize clinical trial outcomes. Through a powerful combination of robust global capabilities, operational and scientific expertise and unsurpassed service, ACM Global acts as an extension of our clients’ clinical teams to develop and execute Smarter Testing strategies that deliver reliable outcomes for their clinical development programs. Operating in more than 60 countries, ACM Global’s analytical team performs more than 15 million diagnostic tests each year from a test menu with more than 1,500 tests spanning all medical disciplines, including pathology, microbiology and molecular diagnostics, flow cytometry, specialized biomarkers, and pharmacogenomics. For more information, visit www.acmgloballab.com, our Central Labs in Focus blog or call +1 866 405 0400.
Wednesday, May 15, 2019
Located at 30 Hagen Drive, the newest vascular location offers state-of-the-art technology to its patients.Read News Article
Wednesday, May 15, 2019
Immediate Care locations averaging higher numbers than usual.Read News Article